Analysts Are Mostly Positive on Intellia Therapeutics This Month



About Intellia Therapeutics

Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system.

CRISPR/Cas9 has the potential to permanently edit disease-associated genes with a single therapy course. It can be used to improve cell therapies for the treatment of immunological diseases and cancer.

Article continues below advertisement

Recent developments

In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles.

The success in the preclinical study should help Intellia file an Investigational New Drug application for further progress on human clinical trials.

Stock performance

On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24. The stock closed ~33% below its 52-week high of $35.99 on March 12. It hit its 52-week low of $16.33 on December 13, 2017.

Article continues below advertisement

Analysts’ recommendations

Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock. One analyst has recommended a “hold” on Intellia Therapeutics in September.

On September 11, Intellia Therapeutics had a consensus 12-month target price of $48.75, reflecting a potential ~80.69% return on investment over the next 12 months.

Peers’ ratings

Of the 22 analysts tracking Spark Therapeutics (ONCE) in September, ~50% have recommended “buys.” Of the eight analysts tracking CRISPR Therapeutics (CRSP), ~75% have recommended “buys.”

On September 10, Spark Therapeutics and CRISPR Therapeutics had consensus 12-month target prices of $69.67 and $66.93, respectively, reflecting ~13.86% and ~34.70% potential returns on investment over the next 12 months.


More From Market Realist